[ad_1]
Cuba announced this Thursday that it will begin clinical trials of two projects for vaccines against covid-19, which increase to four the number of possible drugs of this type developed on the island to combat the pandemic.
Mambisa (administered intranasally) and Abdala (intramuscular), created at the Center for Genetic Engineering and Biotechnology of Cuba, are the most recent ‘candidates’ to mitigate the spread of the pandemic and will undergo two phases of tests to demonstrate their effectiveness. he tells Cubavisión, without saying when the clinical trials will begin.
“Cuba has four candidate vaccines in clinical trials, opinion of the country’s biotechnology and pharmaceutical industry”, The Cuban Biotechnology and Pharmaceutical Industries Business Group (BioCubaFarma), which is state-owned, wrote on Twitter.
Trials of Soberana 01, the first vaccine project against the new coronavirus, began in late August. The process continues to advance without registered incidents and has the participation of more than 700 volunteers.
Unlike other international vaccines whose clinical trials are more advanced and which are being produced using inactive adenoviral vectors or viruses, this Cuban drug is based on a recombinant protein.
Soberana 02, for its part, is a conjugate vaccine, in which a viral antigen and a tetanus toxoid are combined, which has been tested since October 19.
Cuba, which has accumulated 8,075 infections since the start of the pandemic and 133 deaths, has one of the most internationally recognized biotechnology and pharmaceutical industries and currently produces eight vaccines against various diseases, such as meningitis, lung cancer and tumors. solid, among others.
See also:
